Vaxcyte, Inc. (NASDAQ:PCVX) COO Jim Wassil Sells 8,000 Shares

Vaxcyte, Inc. (NASDAQ:PCVX - Get Free Report) COO Jim Wassil sold 8,000 shares of the business's stock in a transaction dated Friday, November 1st. The shares were sold at an average price of $106.80, for a total transaction of $854,400.00. Following the completion of the sale, the chief operating officer now directly owns 205,695 shares of the company's stock, valued at approximately $21,968,226. The trade was a 0.00 % decrease in their position. The sale was disclosed in a document filed with the SEC, which is available through this link.

Jim Wassil also recently made the following trade(s):

• On Tuesday, September 3rd, Jim Wassil sold 10,000 shares of Vaxcyte stock. The shares were sold at an average price of $111.93, for a total transaction of $1,119,300.00.

Vaxcyte Stock Down 0.7 %

Shares of PCVX stock traded down $0.80 on Monday, reaching $106.49. The company had a trading volume of 549,530 shares, compared to its average volume of 829,826. The stock has a market capitalization of $11.89 billion, a PE ratio of -22.75 and a beta of 1.01. Vaxcyte, Inc. has a one year low of $46.16 and a one year high of $121.06. The business's 50-day moving average is $109.48 and its 200 day moving average is $86.36.

Vaxcyte (NASDAQ:PCVX - Get Free Report) last posted its earnings results on Tuesday, August 6th. The company reported ($1.10) EPS for the quarter, topping analysts' consensus estimates of ($1.14) by $0.04. During the same quarter in the prior year, the firm posted ($0.70) earnings per share. On average, sell-side analysts forecast that Vaxcyte, Inc. will post -4.33 earnings per share for the current fiscal year.

Institutional Inflows and Outflows

A number of institutional investors and hedge funds have recently made changes to their positions in the stock. Fidelis Capital Partners LLC acquired a new position in shares of Vaxcyte in the first quarter valued at approximately $37,000. SG Americas Securities LLC acquired a new position in shares of Vaxcyte in the first quarter valued at approximately $298,000. ClariVest Asset Management LLC acquired a new position in shares of Vaxcyte in the first quarter valued at approximately $283,000. Swiss National Bank increased its stake in shares of Vaxcyte by 20.4% in the first quarter. Swiss National Bank now owns 178,000 shares of the company's stock valued at $12,159,000 after buying an additional 30,100 shares during the period. Finally, Russell Investments Group Ltd. acquired a new position in shares of Vaxcyte in the first quarter valued at approximately $1,288,000. Institutional investors own 96.78% of the company's stock.

Analyst Ratings Changes

A number of equities research analysts have recently issued reports on the stock. Bank of America boosted their target price on shares of Vaxcyte from $101.00 to $140.00 and gave the company a "buy" rating in a research report on Wednesday, September 4th. Mizuho boosted their target price on shares of Vaxcyte from $113.00 to $163.00 and gave the company an "outperform" rating in a research report on Tuesday, September 10th. Leerink Partners boosted their target price on shares of Vaxcyte from $106.00 to $153.00 and gave the company an "outperform" rating in a research report on Tuesday, September 3rd. BTIG Research upped their price objective on shares of Vaxcyte from $98.00 to $160.00 and gave the stock a "buy" rating in a research report on Tuesday, September 3rd. Finally, Needham & Company LLC upped their price objective on shares of Vaxcyte from $95.00 to $140.00 and gave the stock a "buy" rating in a research report on Tuesday, September 3rd. Seven equities research analysts have rated the stock with a buy rating, Based on data from MarketBeat.com, Vaxcyte has an average rating of "Buy" and a consensus target price of $147.50.

Vaxcyte Company Profile

Vaxcyte, Inc, a clinical-stage biotechnology vaccine company, develops novel protein vaccines to prevent or treat bacterial infectious diseases. Its lead vaccine candidate is VAX-24, a 24-valent investigational pneumococcal conjugate vaccine for the prevention of invasive pneumococcal disease. The company also develops VAX-31 to protect against emerging strains and to help address antibiotic resistance; VAX-A1, a novel conjugate vaccine candidate to prevent disease caused by Group A Streptococcus; VAX-PG, a novel protein vaccine candidate targeting keystone pathogen responsible for periodontitis; and VAX-GI to prevent Shigella, a bacterial illness.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.